Medically reviewed by Drugs.com. Last updated on Dec 15, 2020.
Applies to the following strengths: 50 mg; 25 mg; 100 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Diabetes Type 2
100 mg orally once a day
-When used in combination with an insulin secretagogue (e.g. sulfonylurea) or insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia.
Use: As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Renal Dose Adjustments
Mild renal impairment (eGFR 45 mL/min/1.73 m2 or greater): No adjustment recommended
Moderate renal impairment (eGFR 30 mL/min/1.73 m2 to less than 45 mL/min/1.73 m2): 50 mg orally once a day
Severe renal impairment (eGFR less than 30 mL/min/1.73 m2): 25 mg orally once a day
Liver Dose Adjustments
Mild or moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: Use caution; no data available
-Hypersensitivity to this drug or any of the product excipients
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Hemodialysis: 25 mg orally once a day
Peritoneal dialysis: 25 mg orally once a day
-May be administered without regard to timing of dialysis
-May take with or without food
-Missed doses should be taken as soon as the patient remembers. More than one dose should not be taken on the same day.
-In clinical trials, sitagliptin has not been shown to improve glycemic control in pediatric patients 10 to 17 years old with type 2 diabetes; this drug is not approved for use in pediatric patients.
-This drug should not be used in patients with type 1 diabetes.
-Has not been studied in patients with a history of pancreatitis; it is unknown whether these patients may be at an increased risk for the development of pancreatitis.
-Assess renal function prior to initiating therapy and periodically thereafter
-Monitor for signs and symptoms of heart failure
-Blood glucose and hemoglobin A1C measurements should be measured periodically to assess efficacy
-Observe for signs and symptoms of pancreatitis
-Patients should be instructed to read the US FDA-approved patient labeling (Medication Guide).
-Instruct patient to report signs and symptoms of pancreatitis; if persistent, severe abdominal pain occurs, seek medical advice promptly.
-Serious allergic reactions may occur; if symptoms occur, seek medical advice promptly.
-Hypoglycemia may occur, more commonly when used in combination with insulin or a sulfonylurea.
-Patients should understand the importance of adhering to dietary instructions and regular physical activity; during periods of stress such as fever, trauma, infection, or surgery, management of diabetes may change and patients should be advised to seek medical advice.
-Instruct patients to contact their health care provider if they develop severe and persistent joint pain.
-Instruct patients to contact their health care provider if they develop signs or symptoms of heart failure.
Frequently asked questions
More about sitagliptin
- Side Effects
- During Pregnancy or Breastfeeding
- Drug Interactions
- En Español
- 125 Reviews
- Drug class: dipeptidyl peptidase 4 inhibitors
- Other brands
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.